After taking metformin at 0800, in which time frame should the patient expect to take another dose?

Clinical Trial

Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes

A Lee et al. Obes Res. 1998 Jan.

Free article

Abstract

Metformin often promotes weight loss in patients with obesity with non-insulin-dependent diabetes mellitus (NIDDM). The mechanism may be attributed to decreased food intake. This study has tested the effect of metformin on satiety and its efficacy in inducing weight loss. Twelve diet-treated NIDDM women with obesity were randomly given two dose levels (850 mg or 1700 mg) of metformin or placebo at 0800 for three consecutive days followed by a meal test on the third day on three occasions using a 3x3 Latin square design. The number of sandwich canapes eaten in three consecutive 10-minute periods beginning at 1400 hours was used to quantitate food intake, and the level of subjective hunger was rated just before the sandwich meal with a linear analogue hunger rating scale at 1400 after a 6-hour fast. The prior administration of metformin produced a reduction in calorie intake after each of the two doses of metformin treatment. The 1700-mg metformin dose had the most marked appetite suppressant action. Similarly, hunger ratings were significantly lowered after metformin, and the effect was most pronounced after the administration of 1700 mg of metformin. To assess the efficacy of metformin in reducing bodyweight, 48 diet-treated NIDDM women with obesity who had failed to lose weight by diet therapy were first placed on a 1200-kcal ADA (American Diabetes Association) diet before being randomized to receive either metformin (850 mg) or placebo twice daily in a double-blind fashion for 24 weeks. A 4-week single-blind placebo lead-in period preceded and a 6-week single-blind placebo period followed the 24-week double-blind treatment period. Subjects treated with metformin continued to lose weight throughout 24 weeks of treatment; their mean maximum weight loss was 8 kg greater than that of the placebo group, with corresponding lower HbA1C and fasting blood glucose levels at the end of the active treatment period. These results indicate that metformin decreases calorie intake in a dose-dependent manner and leads to a reduction in bodyweight in NIDDM patients with obesity.

Similar articles

• Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes.

  Wolever TM, Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW, Ross SA, Ryan EA, Tan MH. Wolever TM, et al. Int J Obes Relat Metab Disord. 1997 Sep;21(9):756-63. doi: 10.1038/sj.ijo.0800468. Int J Obes Relat Metab Disord. 1997. PMID: 9376887 Clinical Trial.

• Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.

  Hoffmann J, Spengler M. Hoffmann J, et al. Am J Med. 1997 Dec;103(6):483-90. doi: 10.1016/s0002-9343(97)00252-0. Am J Med. 1997. PMID: 9428831 Clinical Trial.

• Beneficial effects of metformin in normoglycemic morbidly obese adolescents.

  Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S. Kay JP, et al. Metabolism. 2001 Dec;50(12):1457-61. doi: 10.1053/meta.2001.28078. Metabolism. 2001. PMID: 11735093 Clinical Trial.

• Effects of metformin on weight loss: potential mechanisms.

  Malin SK, Kashyap SR. Malin SK, et al. Curr Opin Endocrinol Diabetes Obes. 2014 Oct;21(5):323-9. doi: 10.1097/MED.0000000000000095. Curr Opin Endocrinol Diabetes Obes. 2014. PMID: 25105996 Review.

Cited by

• Metabolic Action of Metformin.

  Szymczak-Pajor I, Wenclewska S, Śliwińska A. Szymczak-Pajor I, et al. Pharmaceuticals (Basel). 2022 Jun 30;15(7):810. doi: 10.3390/ph25070810. Pharmaceuticals (Basel). 2022. PMID: 35890109 Free PMC article. Review.

• The Mechanism of Action of Biguanides: New Answers to a Complex Question.

  Di Magno L, Di Pastena F, Bordone R, Coni S, Canettieri G. Di Magno L, et al. Cancers (Basel). 2022 Jun 30;14(13):3220. doi: 10.3390/cancers14133220. Cancers (Basel). 2022. PMID: 35804992 Free PMC article. Review.

• Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus.

  Wesling M, D'Souza JJ. Wesling M, et al. Drugs Context. 2022 Jun 14;11:2021-11-7. doi: 10.7573/dic.2021-11-7. eCollection 2022. Drugs Context. 2022. PMID: 35775076 Free PMC article. Review.

• The Association Between Antipsychotics and Weight Gain and the Potential Role of Metformin Concomitant Use: A Retrospective Cohort Study.

  Hakami AY, Felemban R, Ahmad RG, Al-Samadani AH, Salamatullah HK, Baljoon JM, Alghamdi LJ, Ramadani Sindi MH, Ahmed ME. Hakami AY, et al. Front Psychiatry. 2022 May 24;13:914165. doi: 10.3389/fpsyt.2022.914165. eCollection 2022. Front Psychiatry. 2022. PMID: 35686187 Free PMC article.

• Antioxidant and Antihyperglycemic Effects of Ephedra foeminea Aqueous Extract in Streptozotocin-Induced Diabetic Rats.

  Hajleh MNA, Khleifat KM, Alqaraleh M, Al-Hraishat E, Al-Limoun MO, Qaralleh H, Al-Dujaili EAS. Hajleh MNA, et al. Nutrients. 2022 Jun 2;14(11):2338. doi: 10.3390/nu14112338. Nutrients. 2022. PMID: 35684137 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations

• Medical

  • Genetic Alliance
  • MedlinePlus Consumer Health Information
  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program